The use of toceranib phosphate after surgical resection of haemangiosarcoma from the aortic arch in a German Shepherd dog
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16170%2F19%3A43877634" target="_blank" >RIV/62157124:16170/19:43877634 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The use of toceranib phosphate after surgical resection of haemangiosarcoma from the aortic arch in a German Shepherd dog
Popis výsledku v původním jazyce
To report the post-operative outcome and survival of a dog after surgical resection of a haemangiosarcoma from the aortic arch using toceranib phosphate as an adjunctive therapy. Methods: Case report of a single patient treated with metronomic chemotherapy instead of conventional high-dose chemotherapy for adjuvant therapy of hemangiosarcoma of the aortic wall. Results: A 7-year-old male German Shepherd dog presented for investigation of lethargy. Pleural, peritoneal and pericardial effusion were identified, and echocardiography was indicative of a heart-based mass. The mass was surgically excised from the aortic arch and a subtotal pericardiectomy performed. Histology confirmed the mass was an incompletely excised haemangiosarcoma. The patient was started on epirubicin protocol (25mg/m2) but developed a severe septic neutropenia and thrombocytopenia. This recurred following the second treatment of epirubicin despite a dose reduction of 10%. Consequently, the patient was started on metronomic chemotherapy with toceranib phosphate (80mg orally Monday, Wednesday and Friday weekly). Eight months following the diagnosis the patient remains systemically well on metronomic chemotherapy with an excellent quality of life. Repeat staging has been negative for local and distant metastases but shows tissue thickening at the level of the aortic arch. Clinical Significance: Metronomic chemotherapy has been proposed for adjuvant therapy in dogs that do not tolerate conventional anthracycline based chemotherapy protocols. This is the first reported case of the use of a tyrosine kinase inhibitor as an adjuvant therapy for cardiac haemangiosarcoma. Conflict of interest and funding: The authors declared no potential conflicts of interest and no financial support with respect to the research, authorship, and/or publication of this abstract.
Název v anglickém jazyce
The use of toceranib phosphate after surgical resection of haemangiosarcoma from the aortic arch in a German Shepherd dog
Popis výsledku anglicky
To report the post-operative outcome and survival of a dog after surgical resection of a haemangiosarcoma from the aortic arch using toceranib phosphate as an adjunctive therapy. Methods: Case report of a single patient treated with metronomic chemotherapy instead of conventional high-dose chemotherapy for adjuvant therapy of hemangiosarcoma of the aortic wall. Results: A 7-year-old male German Shepherd dog presented for investigation of lethargy. Pleural, peritoneal and pericardial effusion were identified, and echocardiography was indicative of a heart-based mass. The mass was surgically excised from the aortic arch and a subtotal pericardiectomy performed. Histology confirmed the mass was an incompletely excised haemangiosarcoma. The patient was started on epirubicin protocol (25mg/m2) but developed a severe septic neutropenia and thrombocytopenia. This recurred following the second treatment of epirubicin despite a dose reduction of 10%. Consequently, the patient was started on metronomic chemotherapy with toceranib phosphate (80mg orally Monday, Wednesday and Friday weekly). Eight months following the diagnosis the patient remains systemically well on metronomic chemotherapy with an excellent quality of life. Repeat staging has been negative for local and distant metastases but shows tissue thickening at the level of the aortic arch. Clinical Significance: Metronomic chemotherapy has been proposed for adjuvant therapy in dogs that do not tolerate conventional anthracycline based chemotherapy protocols. This is the first reported case of the use of a tyrosine kinase inhibitor as an adjuvant therapy for cardiac haemangiosarcoma. Conflict of interest and funding: The authors declared no potential conflicts of interest and no financial support with respect to the research, authorship, and/or publication of this abstract.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
40301 - Veterinary science
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů